Ignite Creation Date:
2025-12-25 @ 3:18 AM
Ignite Modification Date:
2026-05-20 @ 10:14 PM
Study NCT ID:
NCT01311505
Status:
COMPLETED
Last Update Posted:
2012-07-30
First Post:
2011-02-15
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Bioequivalence Study Comparing Rifampicin In A Fixed-Dose Combination (Rifampicin+Isoniazid, Myrin© 2) And The Reference Drug (Rifampicin, Rimactane®)
Sponsor:
Pfizer
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
B3801001
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None